Bone Metastasis Imaging: Which Test When
Choosing among ⁹⁹ᵐTc bone scan, NaF PET, FDG PET, and tumor-specific tracers by cancer type and lesion biology
Quick Answer
The best test for bone metastases depends on the biology of the lesion and the primary tumor. ⁹⁹ᵐTc-diphosphonate bone scintigraphy and ¹⁸F-NaF PET image the osteoblastic reaction — excellent for sclerotic/mixed mets (breast, prostate) but insensitive to purely lytic disease. FDG-PET images tumor metabolism and detects lytic and marrow-based disease (many solid tumors, myeloma) that the bone scan misses. Tumor-specific tracers — PSMA for prostate, SSTR/DOTATATE for NET — often outperform all of the above within their cancer. The rule: match the tracer to whether the metastasis provokes bone formation (bone scan/NaF), is metabolically active/lytic (FDG), or expresses a specific target (PSMA/SSTR).
The decision in one place
Ask what the metastasis is. Osteoblastic/sclerotic (prostate, breast) → bone scan or NaF PET (they image the bone reaction). Lytic or marrow-based (renal, thyroid, myeloma, lung) → FDG-PET (osteoblastic imaging is falsely negative). Tumor with a specific target → PSMA (prostate) or DOTATATE (NET), often the most sensitive. NaF PET is a higher-resolution, more sensitive version of the bone scan; FDG and target tracers add whole-body soft-tissue staging.
Head-to-head
| Test | Images | Best for | Blind spot |
|---|---|---|---|
| ⁹⁹ᵐTc bone scan (± SPECT/CT) | Osteoblastic reaction | Sclerotic/mixed mets (prostate, breast); wide availability; whole-body | Purely lytic and marrow disease (false negative); superscan pitfall |
| ¹⁸F-NaF PET/CT | Osteoblastic (higher sensitivity/resolution) | Detecting/characterizing bone mets more sensitively than bone scan | Still bone-reaction–based; cost/availability; nonspecific benign uptake |
| FDG-PET/CT | Tumor glucose metabolism | Lytic/marrow disease, aggressive tumors, myeloma; soft tissue too | FDG-low tumors; osteoblastic-only healing can be FDG-quiet |
| PSMA PET/CT | PSMA expression | Prostate bone mets (very sensitive, low PSA) | PSMA-negative dedifferentiated disease; benign PSMA bone uptake |
| DOTATATE PET/CT | SSTR expression | NET bone mets | Dedifferentiated SSTR-negative disease |
How to sequence
By primary tumor:
- Prostate cancer: PSMA PET/CT is now most sensitive for staging/recurrence; conventional bone scan still informs osteoblastic burden and Ra-223 candidacy.
- Breast cancer: bone scan / NaF for sclerotic disease, but add FDG for lytic and visceral/nodal disease — mixed biology is common.
- Renal, thyroid, melanoma, lung (lytic-prone): FDG-PET (bone scan under-detects lytic mets).
- Multiple myeloma: FDG-PET/CT (and whole-body MRI) — the bone scan is classically insensitive because myeloma is lytic with little osteoblastic response.
- Neuroendocrine tumors: DOTATATE PET for SSTR-expressing bone disease.
Interpreting the biology
Bone scintigraphy and NaF detect the osteoblastic host response, not the tumor — so they shine for bone-forming metastases and fail for purely lytic disease that provokes little new bone (the reason a myeloma bone scan can look deceptively normal). FDG and target tracers image the tumor itself, catching lytic and marrow deposits before an osteoblastic reaction develops. This is also why an early treatment response can produce a bone-scan flare (osteoblastic healing transiently increases uptake).
Pitfalls in selection
- Myeloma ≠ bone scan. Use FDG-PET or whole-body MRI/skeletal survey; the bone scan misses lytic myeloma.
- Flare vs progression: increased osteoblastic uptake early after effective therapy may be healing, not progression (see the flare page).
- Benign uptake (degenerative, trauma, Paget) is common on bone scan/NaF and PSMA bone imaging — correlate with CT.
Bottom line
Match the tracer to the biology: bone scan/NaF for osteoblastic mets, FDG for lytic/marrow disease and myeloma, and PSMA/DOTATATE for their specific tumors — often the most sensitive option within that cancer.
Self-Check
Q1. Why does the ⁹⁹ᵐTc bone scan miss purely lytic metastases?
Answer: It images the osteoblastic host reaction, not the tumor; purely lytic disease provokes little new bone formation, so it can be falsely negative — classically in multiple myeloma.
Q2. Which test is preferred for myeloma bone disease, and why not the bone scan?
Answer: FDG-PET/CT (or whole-body MRI/skeletal survey) — myeloma is lytic with minimal osteoblastic response, so the bone scan is insensitive.
Q3. For prostate cancer bone metastases, what is now the most sensitive test, and what role remains for the bone scan?
Answer: PSMA PET/CT is most sensitive (staging/recurrence, low PSA); the conventional bone scan still informs osteoblastic burden and Ra-223 candidacy.
Q4. How does NaF PET relate to the conventional bone scan?
Answer: NaF PET images the same osteoblastic reaction but with higher sensitivity and resolution — a better-performing version of the bone scan, still blind to purely lytic disease.
Key References
- SNMMI/EANM bone scintigraphy and ¹⁸F-NaF PET guidelines; society guidance on FDG-PET and PSMA PET for skeletal staging.
- Comparative literature on osteoblastic vs metabolic vs target-specific bone imaging by tumor type; myeloma imaging recommendations.
Evidence & sources
https://nuc.med/bone-metastasis-imaging-selection/ Report an issue